GlaxoSmithKline (GSK) and Pfizer, global pharmaceutical companies, will join forces. In mid-2019, a joint venture will be established, whose main area of operation will be the OTC market (over-the-counter products). GSK will have a majority share in the new venture – 68%. Pfizer will receive 32% of the shares. Their portfolio will include OTC drugs…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.